Annexon, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Annexon entered a $200M credit facility with Oxford Finance LLC (initial $50M drawn at closing), extending runway to 2028. Lead program tanruprubart shows positive Phase 3 data in GBS with BLA submission expected Q4 2026. Vonaprument Phase 3 ARCHER II trial (659 patients, GA indication) added Month 24 dual primary endpoint alongside Month 15 primary endpoint (both expected Q4 2026 and Q3 2027 respectively), with Month 15 on track. Third program ANX1502 (oral C1 inhibitor) POC data expected Fall 2026. Q2 2026: net loss $55.3M ($0.28/share) vs. $49.2M ($0.34/share) prior year; cash position $209.2M.
Why this rating
Credit facility ($200M, 82% of market cap) materially extends runway and de-risks clinical execution. Two late-stage programs nearing regulatory milestone inflection (BLA, Phase 3 readouts) represent meaningful probability of transformative approvals. Positive early GBS data and dual-endpoint GA strategy reduce execution risk. Relative to company size, capital raise is highly material.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.